Key result
Novel factor VIII-mimetic bispecific antibody provides new therapeutic class for hemophilia A.
This Perspective highlights the groundbreaking development of a bispecific antibody for treating hemophilia A by mimicking factor VIII.
Answers are grounded in this paper and cite their sources.
May expand hemophilia A options; establishes new direction but leaves open need for prospective trials before adoption.
In this Perspective, the 2026 Lasker-DeBakey Clinical Medical Research Award winners describe the development of a bispecific antibody that mimics blood coagulation factor VIII, revolutionizing the treatment of hemophilia, a life-threatening bleeding disorder caused by lack of factor VIII.
No takes yet. Share an insight, caveat, or question.
Hattori et al. (2026) studied this question. A bispecific antibody mimicking blood coagulation factor VIII was developed as a revolutionary new class of medicine for the treatment of hemophilia A.
Synapse has enriched 10 related papers. Consider them for comparative context: